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Abstract
Background: DYT11 myoclonus-dystonia (M-D) syndrome is a neurological movement disorder characterized by myoclonic
jerks and dystonic postures or movement that can be alleviated by alcohol. It is caused by mutations in SGCE encoding e-
sarcoglycan (e-SG); the mouse homolog of this gene is Sgce. Paternally-inherited Sgce heterozygous knockout (Sgce KO)
mice exhibit myoclonus, motor impairment and anxiety- and depression-like behaviors, modeling several clinical symptoms
observed in DYT11 M-D patients. The behavioral deficits are accompanied by abnormally high levels of dopamine and its
metabolites in the striatum of Sgce KO mice. Neuroimaging studies of DYT11 M-D patients show reduced dopamine D2
receptor (D2R) availability, although the possibility of increased endogenous dopamine, and consequently, competitive D2R
occupancy cannot be ruled out.
Methodology/Principal Findings: The protein levels of striatal D2R, dopamine transporter (DAT), and dopamine D1
receptor (D1R) in Sgce KO mice were analyzed by Western blot. The striatal dopamine release after amphetamine injection
in Sgce KO mice were analyzed by microdialysis in vivo. The striatal D2R was significantly decreased in Sgce KO mice without
altering DAT and D1R. Sgce KO mice also exhibited a significant increase of dopamine release after amphetamine injection
in comparison to wild-type (WT) littermates.
Conclusion/Significance: The results suggest e-SG may have a role in the regulation of D2R expression. The loss of e-SG
results in decreased striatal D2R, and subsequently leads to increased discharge of dopamine which could contribute to the
behavioral impairment observed in DYT11 dystonia patients and in Sgce KO mice. The results suggest that reduction of
striatal D2R and enhanced striatal dopamine release may contribute to the pathophysiology of DYT11 M-D patients.
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Introduction
Dystonia is a neurological disorder characterized by involuntary
contractions of both agonist and antagonist muscles of affected
body regions that cause twisting and abnormal movements or
postures [1]. M-D is a childhood onset movement disorder,
clinically characterized by the presence of ‘lighting-like’ myoclonic
jerks and dystonic postures or movements that can be alleviated by
alcohol [2]. DYT11 M-D patients often show psychiatric
abnormalities including alcohol abuse, depression, anxiety, panic
attacks, and obsessive-compulsive disorder [3,4,5]. DYT11 M-D is
caused by mutations in SGCE (Sgce in the mouse) on chromosome
7q21 coding for e-SG [3]. It is inherited in an autosomal dominant
manner with SGCE maternally imprinted probably by promoter
methylation [6,7]. Exclusive paternal expression of e-SG in the
brain is confirmed in both mice [8,9] and humans [10]. Both
nonsense and missense mutations have been found in DYT11 M-
D patients. The missense mutations usually result in a shift of
translational reading frame and introduce premature termination
codon [3,11]. Several SGCE missense mutations in extracellular
domain of e-SG impair membrane trafficking of the mutant
proteins in cultured cells [12]. Taken together, these results suggest
that the loss of function of e-SG causes DYT11 M-D.
The sarcoglycans are a family of plasma membrane proteins,
which consists of six different isoforms, a, b, c, d, e and f [13]. The
a, b, c, and d-sarcoglycans form a heterotetrameric complex that
associates with dystroglycan at the plasma membrane in muscle.
Mutations in a, b, c, and d-sarcoglycans lead to muscle membrane
instability and result in autosomal recessive limb-girdle muscular
dystrophies (LGMD). e-SG is widely expressed in many tissues
including brain [3,14]. Fluorescence in situ hybridization (FISH)
and immunohistochemistry studies have revealed that e-sarcogly-
can mRNA is expressed at high level in cholinergic neurons of
dorsal raphe nucleus and in dopaminergic neurons of the
substantia nigra pars reticulata, pars compacta, and ventral
tegmental area [15]. The function of e-SG is largely unknown.
Subcellular fractionation of the mouse brain homogenate have
revealed e-SG is relatively enriched in post-and pre-synaptic
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transmission of the central nervous system [16]. This is supported
by recent brain-specific knockout of Sgce in mice. Specific knockout
of Sgce in striatum or cerebellar Purkinje cells results in deficits of
motor learning, coordination and balance [17,18].
Although the pathophysiological nature of dystonia is largely
elusive, basal ganglia, especially striatal dopaminergic system is
thought to play a major role. DYT5 dystonia is caused by
mutations in either GTP cyclohydrolase gene [19] or tyrosine
hydroxylase [20,21]. Mutations in both genes have direct impact
on dopamine synthesis. Clinical neuroimaging studies in dystonia
patients, including DYT1 dystonia, idiopathic cervical dystonia,
and nocturnal myoclonus have showed reduced in vivo striatal D2R
binding [22,23,24]. Furthermore, a recent neuroimaging study has
revealed reduced striatal D2R binding in DYT11 M-D patients
[25]. In addition, a missense mutation (Val154Ile) in a highly
conserved region of the D2R was found in one M-D family [2].
D2R-mediated dopaminergic neurotransmission is known to have
a key role in the control of movement [26], in reward and
reinforcement mechanisms [27], and in psychiatric disorders [28].
Pharmacological agents blocking D2R can result in a dystonic
phenotype [29].
We previously reported generation of Sgce KO mice by using
Cre-loxP system to flank exon 4 of Sgce and demonstrated that
expression of e-SG is fully abolished in paternally inherited Sgce
heterozygous KO mice [9]. The Sgce KO mice exhibit myoclonus,
motor impairments, anxiety- and depression-like behaviors [30],
which resemble several clinical symptoms observed in DYT11 M-
D patients [2]. Moreover, these are accompanied by significantly
high levels of dopamine and its metabolites in the striatum [30],
implicating abnormal striatal dopaminergic function in Sgce KO
mice. In this study, we aim to determine the nature of the
dopaminergic dysfunction and found significantly reduced level of
striatal D2R with normal level of D1R and DAT in Sgce KO mice.
Furthermore, we found increased discharge of striatal dopamine in
the mutant mice after amphetamine injection. The results suggest
that striatal dopaminergic dysfunction contributes to the patho-
physiology of DYT11 M-D.
Results
Increased striatal dopamine release in Sgce KO mice
Previous study has shown increased dopamine and its
metabolites in the striatum of Sgce KO mice accompanied with
behavioral deficits similar to DYT11 M-D patients [30]. To
examine whether the striatal dopaminergic transmission is
changed in Sgce KO mice, we used microdialysis to monitor
extracellular dopamine levels after amphetamine injection in
conscious, freely moving mice as previously described [31].
Amphetamine, a potent psychostimulant, enhances the release of
dopamine from pre-synaptic dopaminergic terminals [32]. A single
subcutaneous (s.c.) administration of amphetamine (5 mg/kg)
induced a remarkable increase of striatal extracellular dopamine
level in Sgce KO mice (1,620645%, n=6) in comparison to their
WT littermates (1,2606118%, n=8, p,0.05) 60 minutes after
injection (Fig. 1A). Data from each animal were normalized to the
corresponding pre-treatment baseline and expressed as a percent
of base line of extracellular dopamine level. Repeated ANOVA
analysis revealed a significant difference of amphetamine pre-
treatment and post-treatment [F (1, 12)=3.90, p,0.05]. No
significant difference in the basal extracellular dopamine levels was
found. Probe locations were verified in all mice at the end of the
microdialysis experiment (Fig. 1B).
Decreased striatal D2R without altering D1R and DAT
Neuroimaging studies have revealed decreased in vivo striatal
D2R availability in clinical DYT11 M-D patients [25]. In
addition, a recent study has reported dopaminergic neuron-
specific D2R knockout results in elevated dopamine synthesis and
release, hyperactivity and supersensitivity to cocaine [33]. To
examine whether loss of e-SG alters the expression of D2R in the
striatum, we analyzed expression level of D2R in Sgce KO and
control littermates by Western blot. The D1R, D2R, and DAT
levels were standardized with glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) as a loading control. Striatal D2R was
significantly reduced in Sgce KO mice in comparison to control
littermates (p,0.01; Fig. 2A), while striatal D1R and DAT
remained unchanged (Fig. 2B, C).
Discussion
Striatal dopamine and their metabolites are increased in Sgce
KO mice [30]. To determine the nature of this dopaminergic
dysfunction, we used microdialysis to examine the striatal
dopamine release in Sgce KO mice. We found significantly
increased extracellular dopamine after administration of amphet-
amine in Sgce KO mouse compared to their WT littermates. Next,
to determine if this abnormal release of dopamine in the striatum
observed was associated with dysfunction of dopamine receptors
or transporter, we used Western blot technique to assess the
expression levels of D2R, DAT, and D1R in the striatum and
found that D2R was significant decreased without altering D1R
and DAT. These results suggest e-SG may have a role in the
regulation of D2R expression. The loss of e-SG results in
decreased striatal D2R, and subsequently leads to increased
discharge of dopamine which could contribute to the behavioral
impairment observed in Sgce KO mice and DYT11 M-D patients.
Despite of significantly increased striatal dopamine turnover,
the level of striatal dopamine is significantly higher in the Sgce KO
mice, which indicated a lack of autoreceptor function [30]. Pre-
synaptic D2R is present in the soma, dendrites and synaptic
terminals of dopaminergic neurons, serving as autoreceptor and
providing negative feedback regulation of firing rate [34,35],
synthesis and release of dopamine in the terminals [33,36].
Amphetamine is well known to elevate extracellular dopamine
levels by reversing DAT and inhibiting dopamine re-uptake
through DAT, which results in significantly inducing stimulation-
independent non-vesicular dopamine efflux. Dramatic increase of
dopamine activates the pre-synaptic D2 receptor and inhibits the
activity of dopamine neurons and subsequently inhibits stimula-
tion-dependent exocytosis of dopamine in the terminals [37]. This
inhibition appears to be defective in Sgce KO mice (Fig. 1A, 2A).
The D2R results we obtained from Western blot include both
post-synaptic D2R on the medium spiny neurons and pre-synaptic
D2R on the dopaminergic terminals from substantia nigra. Since
majority of striatal D2R are located on the post-synaptic medium
spiny neurons, the reduction of striatal D2R may just reflect those
in the post-synaptic neurons (Fig. 2A). However, decreased striatal
post-synaptic D2R alone will not affect dopamine release from
terminals of dopaminergic neurons after amphetamine challenging
(Fig. 1A) and result in significantly increased striatal tissue
dopamine observed in Sgce KO mice [30]. Furthermore,
conditional knockout mice lacking D2 autoreceptor are hyperac-
tive in open field test and show enhanced dopamine release in
dorsal striatum and elevated tyrosine hydroxylase activity [33].
Although conditional D2 autoreceptor KO mice exhibit normal
motor coordination and no signs of anxiety-like behavior, which
differ from the behavioral abnormalities observed in Sgce KO mice
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in such D2R conditional KO mice. Alternatively, additional
pathways other than D2R may have been disrupted in Sgce KO
mice that lead to motor deficits and anxiety-like behaviors. Taken
together, it is likely that both pre- and post-synaptic D2R are
reduced in the Sgce KO mice.
It is not known how loss of e-SG led to D2R reduction in the
Sgce KO mice. Although the functions of other sarcoglycans are
well documented, the functions of e- and f-sarcoglycans, which
express widely in central nervous system, are less clear.
Sarcoglycan family is well known for its major role in stabilizing
membrane through forming complex with dystroglycan and
dystrophin during the muscle contraction. Mutations in a, b, c,
and d-sarcoglycan result in autosomal recessive limb-girdle
muscular dystrophies (LGMD) [13]. mRNA for e-SG is expressed
at high level in dopaminergic neurons [15], suggesting that it may
have an important role in stabilizing the membrane of dopami-
nergic neurons. Indeed, our results show that elimination of e-SG
resulted in the reduction of D2R in the striatum (Fig. 2A). We
previously reported brain-specific alternatively spliced mRNA
variants of e-SG in mice. These two variants possess unique C-
terminal sequences which are similar to PDZ-binding motifs [9].
Many G-protein coupled receptors contain a PDZ binding motif
at their C-terminals enabling other PDZ proteins to associate and
scaffold multi-protein complexes that can modulate receptor
properties such as trafficking, signaling, receptor stability and cell
distribution [38]. Whether e-SG acts in a similar fashion to
modulate D2R remains to be investigated in the future studies.
Western blot analysis showed a selective reduction of striatal
D2R without altering mRNA level of striatal D2R (Fig. 2 and Fig.
S1). It is not known how loss of e-SG specifically affects D2R
alone. Amphetamine and its derivatives release dopamine from
dopaminergic terminals and cause excessively increased level of
extracellular dopamine [32]. Addictive drug is thought to ‘‘hijack’’
normal natural rewards system, such as food or sexual activity, by
quickly elevating the level of extracellular dopamine to exert their
reinforcing properties. Upon dopamine stimulation, agonist-
activated D1R and D2R are rapidly silenced by undergoing
endocytosis followed by trafficking to early endosomes. D1R is
recycled back to the plasma membrane after desensitization, while
D2R is targeted by interaction with GPCR-associated sorting
protein and degraded in lysosomes [39]. e-SG located on the cell
membrane may have important roles in regulating endocytic
degradation of D2R.
In conclusion, we found significant and selective reduction of
striatal D2R in Sgce KO mice that is consistent with the
Figure 1. Extracellular dopamine levels in the mouse striatum after amphetamine administration. (A) Amphetamine (5 mg/kg, s.c.) was
administrated to conscious mice. Extracellular levels of dopamine in the striatum were measured by in vivo microdialysis. The basal extracellular
dopamine levels were 4.01360.267 pg/20 ml (mean 6 SEM of 6 Sgce KO mice) and 4.29760.412 pg/20 ml (mean 6 SEM of 8 WT littermates). The data
are the mean 6 SEM of 6 or 8 mice (*p,0.05). (B) A representative coronal section of the striatum of probe implanted mouse. The black arrow
indicates the location of the probe. Scale bar represents 500 mm.
doi:10.1371/journal.pone.0033669.g001
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of D2 autoreceptor in dopaminergic neurons may result in
enhanced dopamine synthesis in terminals [30] and increased
dopamine release after amphetamine injection in the striatum
(Fig. 1A). These results support the idea that basal ganglia play
very important role in manifesting of dystonia, and suggest that
loss of e-SG may influence the homeostasis of D2R.
Limitations
The reduction of striatal D2 receptor (Figure 2A) reflects the
combination of pre-synaptic and post-synaptic D2 receptors.
Although Western blotting result showed the expression level of
striatal DAT is not altered and microdialysis experiment showed
that extracellular level of dopamine returned to basal level after
the stimulation, however the alteration of DAT functions cannot
be completely ruled out. There is alternative explanation of
obtained results that is due to unknown mechanisms underlying
enhanced striatal dopamine release from loss of e-SG protein, and
subsequently increased ligand occupied D2 receptors which
became targets of endocytic desensitization process.
Materials and Methods
Animals
All experiments were carried out in compliance with the
USPHS Guide for Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use Committee at
the University of Alabama at Birmingham with Animal Protocol
Number 10008918. Sgce heterozygous KO male mice were crossed
with C57BL/6 female mice to obtain paternally-inherited Sgce
heterozygous KO (Sgce KO) mice and WT littermates as
previously described [9]. Genotyping for Sgce KO mice and WT
littermates was performed by multiplex PCR using SgceE4U (59-
CTGTAACAACACACTGGAGTAG-39) and SgceE4D (59-AC-
AGCTTTGAACTACTTTGTGCA-39) primers for the deleted
exon 4 locus [9] and DAT-Up (59-TCCATAGCCAATCTCTC-
CAGTC-39) and DAT-Lwt (59-TTGATGAGGGTGGAGTT-
GGTCA-39) primer sets for dopamine transporter gene as an
internal control [17]. Mice were housed under a 12-h-light/dark
cycle with free access to food and water. All experiments were
performed by investigators blind to the genotypes and the animals
were decoded after all experiments were finished.
Drugs administration
Amphetamine (5 mg/kg; Sigma-Aldrich Corporation, St Louis,
MO) was dissolved in physiological saline and was injected
subcutaneously in a volume of 10 ml/kg, as previously described
[40].
In vivo microdialysis
Five-month-old Sgce KO mice (n=6) and their WT littermates
(n=8) were used in microdialysis study, procedure was performed
in alert, freely moving mice as previously described [31]. Briefly,
mice were anesthetized with ketamine/xylezine (100/10 mg/kg)
before the stereotaxic implantation of a probe (Eicom; P-I-6-02)
into the striatum at coordinates (+0.0 mm anteroposterior,
+2.5 mm mediolateral from the bregma, and 24.4 mm dorso-
ventral with respect to dura). Probes were secured onto the skull
using stainless-steel screws and dental acrylic. Twenty-four hours
after surgery, in vivo microdialysis was performed on conscious
mice. Probe was perfused continuously with artificial CSF
(147 mM NaCl, 4 mM KCl, and 2.3 mM CaCl2) at a flow rate
of 1.5 ml/min. The dialysate was collected in 20-min fractions. Six
samples were obtained in order to establish the baseline levels of
extracellular dopamine prior to the administration of amphet-
amine. Dopamine level of microdialysis samples were measured by
high-performance liquid chromatography (HPLC) using a re-
versed phase column (Dionex ESA MD-15063.2 150 mm
Dionex, Chelmsford, MA, USA), as previously described [41].
Probe locations were verified in all mice at the end of the
microdialysis experiment. The animal was anaesthetized with
ketamine/xylezine (100/10 mg/kg) and perfused transcardially
with 4% paraformaldehyde in saline and brains were removed and
placed in fixative overnight at 4uC. After equilibrated in 30%
sucrose in 0.1 M phosphtate buffer, the brains were sectioned.
Coronal sections were cut at 50 mm thickness using a sliding
microtome (Histoslide 2000, Reichert-Jung). The sections were
Nissl stained.
Western blot analysis
Striatum was dissected from brains of 5-month-old Sgce KO
mice (n=4) and WT littermates (n=3). The tissue was
homogenized in 200 ml of ice-cold lysis buffer contained 50 mM
Tris-Cl (pH 7.4), 175 mM NaCl, 5 mM EDTA with a protease
inhibitor cocktail tablet (Roche) and followed by sonication for
10 sec. Triton X-100 was added to 1% w/v final concentration
and the mixture was incubated on ice for 30 min and centrifuged
at 10,0006g for 15 min at 4uC as described earlier [8]. The
protein concentration was measured by the Bradford assay with
bovine serum albumin (BSA; Fisher Scientific) as standards. The
homogenates were mixed with the SDS-PAGE loading buffer and
boiled for 5 min, incubated on ice for 1 min, and then centrifuged
Figure 2. Western blot analysis of striatal D1R, D2R and DAT.
Western blot analysis by using the striatal protein extracts from
paternally inherited Sgce KO mice and their WT littermates. The
representative bands D2R (Fig. 2A), D1R (Fig. 2C), DAT (Fig. 2B), and
GAPDH are shown in the left side, and the quantified results are shown
in the right side. The vertical bars represent means 6 SEM of 3 or 4 mice
(**p,0.01).
doi:10.1371/journal.pone.0033669.g002
Altered Striatal Dopaminergic Function in DYT11
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33669for 5 min to obtain the supernatant. Of the samples, 30 mg was
loaded on a 10% SDS-PAGE and the separated proteins were
transferred to the PVDF membrane. After blocking with 5% BSA
or 5% non-fat milk (Bio-Rad) TBS-T buffer contained 20 mM
Tris-Cl (pH 7.6), 137 mM NaCl, 0.1% Tween 20, the membranes
were incubated overnight at 4uC with rabbit anti- dopamine D2
receptor (Millipore, AB5084P) at 1:500 dilution in 5% BSA TBS-
T buffer, goat anti-dopamine D1 receptor (Santa Cruz, sc-31478)
at 1:200 dilution and rabbit anti-dopamine transporter (Millipore,
AB1591P) at 1:500 dilution in 5% non-fat milk TBS-T buffer.
Membranes were washed for three times and then incubated with
bovine anti-rabbit IgG-HRP (Santa Cruz, sc-2370) or donkey anti-
goat IgG-HRP (Santa Cruz, sc-2020) in the 5% non-fat milk TBS-
T at room temperature for 1 hour. GAPDH was used as a loading
control, and probed with HRP-conjugated GAPDH antibody
(Santa Cruz, sc-25778). The band was detected by using Super
Signal West Pico Chemiluminescent Substrate (Thermo Scientif-
ic). The signals were captured by Alpha Innotech FluorChem FC2
and quantified with UN-SCAN-IT gel (Silk Scientific) software.
Each Western blot experiment was repeated three times.
RNA preparation and RT-PCR analysis
Striatum was dissected from brains of 4-month-old Sgce KO
mice (n=2) and WT littermates (n=2). RNA was extracted from
striatum by using RNeasy Fibrous Tissue Mini Kits (Qiagen,
Valencia, CA, USA) according to the manufacturer’s protocol;
cDNA was generated from 1 mg of total RNA using random
primers and SuperScript II reverse transcriptase (Invitrogen,
Carlsbad, CA, USA). PCR was performed using the cDNA as
template with the following primer sets: forward D2S (59-
CACCACTCAAGGATGCTGCCCG-39), and reverse D2E8
(59-TTGCTATGTAGACCGTGGTGGGATG-39) for dopamine
receptor D2S; forward D2E7 (59-GGAGTTTCCCAGTGAA-
CAGGCGG- 39), and reverse D2E8 for dopamine receptor D2L
[42]; forward E1 (59-CACCCGCGAGCACAGCTTCTTTG-39),
and reverse E2 (59-AATACAGCCCGGGGAGCATCGTC-39)
for b-actin. PCR products were separated by 2% agarose gel
electrophoresis and visualized by ethidium bromide staining [43].
Statistical analysis
The data are presented as the mean 6 standard error of the
mean (SEM). The computation was carried out using the
STATVIEW 5.0J software (STATVIEW 5.0 J, Tokyo, Japan).
The data from the microdialysis were analyzed by repeated
ANOVA, comparisons of WT and KO groups were analyzed
using student’s t-test. The data of the Western blot were analyzed
by One-way ANOVA. For all analyses, a p-value less than 0.05
was considered statistically significant (*p,0.05, **p,0.01).
Supporting Information
Figure S1 RT-PCR analysis of striatal D2R. Semiquanti-
tative RT-PCR analysis of RNA samples extracted from striatum
of sgce KO and their WT littermates, b-actin was used as control
in this test. The quantified results are shown in the right side. The
vertical bars represent means 6 SEM of 2 pairs of mice.
(EPS)
Acknowledgments
We thank Kevin Feng and the staff for animal care, Alena Samal and Miki
Jinno for their technical assistance, and Dr. Yuan-Hu Jin for discussion and
suggestion.
Author Contributions
Conceived and designed the experiments: LZ DGS YL. Performed the
experiments: LZ. Analyzed the data: LZ. Contributed reagents/materials/
analysis tools: LZ FY DSP DGS YL. Wrote the paper: LZ DGS YL.
References
1. Fahn S (1988) Concept and classification of dystonia. Adv Neurol 50: 1–8.
2. Klein C, Brin MF, Kramer P, Sena-Esteves M, de Leon D, et al. (1999)
Association of a missense change in the D2 dopamine receptor with myoclonus
dystonia. Proc Natl Acad Sci U S A 96: 5173–5176.
3. Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, et al. (2001)
Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia
syndrome. Nat Genet 29: 66–69.
4. Doheny DO, Brin MF, Morrison CE, Smith CJ, Walker RH, et al. (2002)
Phenotypic features of myoclonus-dystonia in three kindreds. Neurology 59:
1187–1196.
5. Misbahuddin A, Placzek M, Lennox G, Taanman JW, Warner TT (2007)
Myoclonus-dystonia syndrome with severe depression is caused by an exon-
skipping mutation in the epsilon-sarcoglycan gene. Mov Disord 22: 1173–1175.
6. Grabowski M, Zimprich A, Lorenz-Depiereux B, Kalscheuer V, Asmus F, et al.
(2003) The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia
syndrome, is maternally imprinted. Eur J Hum Genet 11: 138–144.
7. Piras G, El Kharroubi A, Kozlov S, Escalante-Alcalde D, Hernandez L, et al.
(2000) Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-
sarcoglycan are maternally imprinted genes: identification by a subtractive
screen of novel uniparental fibroblast lines. Mol Cell Biol 20: 3308–3315.
8. Yokoi F, Yang G, Li J, DeAndrade MP, Zhou T, et al. (2010) Earlier onset of
motor deficits in mice with double mutations in Dyt1 and Sgce. J Biochem 148:
459–466.
9. Yokoi F, Dang MT, Mitsui S, Li Y (2005) Exclusive paternal expression and
novel alternatively spliced variants of epsilon-sarcoglycan mRNA in mouse
brain. FEBS Lett 579: 4822–4828.
10. Ritz K, van Schaik BD, Jakobs ME, van Kampen AH, Aronica E, et al. (2011)
SGCE isoform characterization and expression in human brain: implications for
myoclonus-dystonia pathogenesis? Eur J Hum Genet 19: 438–444.
11. Tezenas du Montcel S, Clot F, Vidailhet M, Roze E, Damier P, et al. (2006)
Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic
syndromes. J Med Genet 43: 394–400.
12. Esapa CT, Waite A, Locke M, Benson MA, Kraus M, et al. (2007) SGCE
missense mutations that cause myoclonus-dystonia syndrome impair epsilon-
sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination
and torsinA. Hum Mol Genet 16: 327–342.
13. Ozawa E, Mizuno Y, Hagiwara Y, Sasaoka T, Yoshida M (2005) Molecular and
cell biology of the sarcoglycan complex. Muscle Nerve 32: 563–576.
14. Xiao J, LeDoux MS (2003) Cloning, developmental regulation and neural
localization of rat epsilon-sarcoglycan. Brain Res Mol Brain Res 119:
132–143.
15. Chan P, Gonzalez-Maeso J, Ruf F, Bishop DF, Hof PR, et al. (2005) Epsilon-
sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp
Neurol 482: 50–73.
16. Nishiyama A, Endo T, Takeda S, Imamura M (2004) Identification and
characterization of epsilon-sarcoglycans in the central nervous system. Brain Res
Mol Brain Res 125: 1–12.
17. Yokoi F, Dang MT, Zhou T, Li Y (2012) Abnormal nuclear envelopes in the
striatum and motor deficits in DYT11 myoclonus-dystonia mouse models. Hum
Mol Genet 21: 916–925.
18. Yokoi F, Dang MT, Yang G, Li J, Doroodchi A, et al. (2012) Abnormal nuclear
envelope in the cerebellar Purkinje cells and impaired motor learning in DYT11
myoclonus-dystonia mouse models. Behav Brain Res 227: 12–20.
19. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, et al. (1994) Hereditary
progressive dystonia with marked diurnal fluctuation caused by mutations in the
GTP cyclohydrolase I gene. Nat Genet 8: 236–242.
20. Knappskog PM, Flatmark T, Mallet J, Ludecke B, Bartholome K (1995)
Recessively inherited L-DOPA-responsive dystonia caused by a point mutation
(Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 4: 1209–1212.
21. Ludecke B, Bartholome K (1995) Frequent sequence variant in the human
tyrosine hydroxylase gene. Hum Genet 95: 716.
22. Asanuma K, Ma Y, Okulski J, Dhawan V, Chaly T, et al. (2005) Decreased
striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia
mutation. Neurology 64: 347–349.
23. Naumann M, Pirker W, Reiners K, Lange KW, Becker G, et al. (1998) Imaging
the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic
cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT.
Mov Disord 13: 319–323.
24. Staedt J, Stoppe G, Kogler A, Riemann H, Hajak G, et al. (1995) Nocturnal
myoclonus syndrome (periodic movements in sleep) related to central dopamine
D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci 245: 8–10.
Altered Striatal Dopaminergic Function in DYT11
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e3366925. Beukers RJ, Booij J, Weisscher N, Zijlstra F, van Amelsvoort TA, et al. (2009)
Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur J Nucl Med
Mol Imaging 36: 269–274.
26. Wang Y, Xu R, Sasaoka T, Tonegawa S, Kung MP, et al. (2000) Dopamine D2
long receptor-deficient mice display alterations in striatum-dependent functions.
J Neurosci 20: 8305–8314.
27. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine
receptors: from structure to function. Physiol Rev 78: 189–225.
28. Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism
in the promoter region of the dopamine D2 receptor gene is associated with
schizophrenia. Hum Mol Genet 6: 577–582.
29. Skidmore F, Reich SG (2005) Tardive Dystonia. Curr Treat Options Neurol 7:
231–236.
30. Yokoi F, Dang MT, Li J, Li Y (2006) Myoclonus, motor deficits, alterations in
emotional responses and monoamine metabolism in epsilon-sarcoglycan
deficient mice. J Biochem 140: 141–146.
31. Zhang L, Shirayama Y, Iyo M, Hashimoto K (2007) Minocycline attenuates
hyperlocomotion and prepulse inhibition deficits in mice after administration of
the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 32:
2004–2010.
32. Sulzer D (2011) How addictive drugs disrupt presynaptic dopamine neurotrans-
mission. Neuron 69: 628–649.
33. Bello EP, Mateo Y, Gelman DM, Noain D, Shin JH, et al. (2011) Cocaine
supersensitivity and enhanced motivation for reward in mice lacking dopamine
D2 autoreceptors. Nat Neurosci 14: 1033–1038.
34. Ford CP, Gantz SC, Phillips PE, Williams JT (2010) Control of extracellular
dopamine at dendrite and axon terminals. J Neurosci 30: 6975–6983.
35. Paladini CA, Robinson S, Morikawa H, Williams JT, Palmiter RD (2003)
Dopamine controls the firing pattern of dopamine neurons via a network
feedback mechanism. Proc Natl Acad Sci U S A 100: 2866–2871.
36. Wolf ME, Roth RH (1990) Autoreceptor regulation of dopamine synthesis.
Ann N Y Acad Sci 604: 323–343.
37. Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D (2003) Presynaptic regulation
of dopaminergic neurotransmission. J Neurochem 87: 273–289.
38. Magalhaes AC, Dunn H, Ferguson SS (2011) Regulation of G Protein-Coupled
Receptor Activity, Trafficking and Localization by Gpcr-Interacting Proteins.
Br J Pharmacol.
39. Bartlett SE, Enquist J, Hopf FW, Lee JH, Gladher F, et al. (2005) Dopamine
responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad
Sci U S A 102: 11521–11526.
40. Zhang L, Kitaichi K, Fujimoto Y, Nakayama H, Shimizu E, et al. (2006)
Protective effects of minocycline on behavioral changes and neurotoxicity in
mice after administration of methamphetamine. Prog Neuropsychopharmacol
Biol Psychiatry 30: 1381–1393.
41. Balcioglu A, Kim MO, Sharma N, Cha JH, Breakefield XO, et al. (2007)
Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem
102: 783–788.
42. Dang MT, Yokoi F, Cheetham CC, Lu J, Vo V, et al. (2012) An anticholinergic
reverses motor control and corticostriatal LTD deficits in Dyt1 DeltaGAG
knock-in mice. Behav Brain Res 226: 465–472.
43. Zhang L, Haraguchi S, Koda T, Hashimoto K, Nakagawara A (2011) Muscle
atrophy and motor neuron degeneration in human NEDL1 transgenic mice.
J Biomed Biotechnol 2011: 831092.
Altered Striatal Dopaminergic Function in DYT11
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33669